Key result
Ionic contrast ioxaglate links to lower thrombin generation and platelet activation versus non-ionic iopromide.
Why the study?
Does an ionic X-ray contrast agent (ioxaglate) reduce platelet activation and thrombin generation compared to a non-ionic agent (iopromide) in patients undergoing coronary angiography?
Observational (n=40)
Does an ionic X-ray contrast agent (ioxaglate) reduce platelet activation and thrombin generation compared to a non-ionic agent (iopromide) in patients undergoing coronary angiography?
Ionic contrast agents like ioxaglate may offer a more favorable hemostatic profile by reducing platelet activation and thrombin generation compared to non-ionic agents during cardiac catheterization.
May favor ionic contrast in high-thrombosis-risk procedures; leaves open whether this improves clinical outcomes.
The aim of the present study was to evaluate the effects of ionic (ioxaglate) and non-ionic (iopromide) contrast media on haemostatic parameters ex vivo. In 40 patients undergoing coronary angiography, platelet function (platelet reactivity and serotonin concentration) and coagulation markers [thrombin-antithrombin III complexes, prothrombin fragments (F1+2) and the D-dimers] were measured. The use of an ionic X-ray contrast agent (XCA) (ioxaglate) in diagnostic cardiac catheterisation angiography is associated with lower thrombin generation and lower activation of the platelet system than when a non-ionic XCA is employed (iopromide). The results thus confirm the results of various in vitro studies and animal investigations.
No takes yet. Share an insight, caveat, or question.
Jung et al. (2002) conducted an observational in undergoing coronary angiography (n=40). Ionic X-ray contrast agent (ioxaglate) vs. Non-ionic X-ray contrast agent (iopromide) was evaluated on platelet function (platelet reactivity and serotonin concentration) and coagulation markers (thrombin-antithrombin III complexes, prothrombin fragments, and D-dimers). An ionic X-ray contrast agent (ioxaglate) was associated with lower thrombin generation and platelet activation during diagnostic cardiac catheterisation compared to a non-ionic agent (iopromide).